Which medications in the drug class Anti-BCMA Antibodies are used in the treatment of Multiple Myeloma?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Anti-BCMA Antibodies

This drug class are antibody-drug conjugates. The antibody component is an afucosylated IgG1 directed against B-cell maturation agent (BCMA), a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is MMAF, a microtubule inhibitor.

Belantamab mafodotin (Belantamab mafodotin-blmf, Blenrep)

Upon binding to BCMA, belantamab mafodotin-blmf is internalized followed by release of MMAF via proteolytic cleavage. The released MMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis. It also has antitumor activity in multiple myeloma cells and mediated killing of tumor cells through MMAF-induced apoptosis, as well as by tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). It is indicated for relapsed or refractory MM in patients who were previously treated with 4 or more prior therapies.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!